Coherus BioSciences Receives Complete Response Letter from FDA for its Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Coherus BioSciences Receives Complete Response Letter from FDA for its Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)

Coherus Biosciences (CHRS) Neulasta Biosimilar Delay 'Appears Resolvable' - Cowen

June 12, 2017 12:29 PM EDT

Cowen analyst Ken Cacciatore is the latest to defend Coherus Biosciences (NASDAQ: CHRS), reiterating an Outperform rating and price target of $45. Cacciatore said while the Neulasta biosimilar delay is disappointing, the issues appear resolvable.

Cacciatore said based on an initial evaluation by the... More

Coherus Biosciences (CHRS) PT Lowered to $37 at Baird Following FDA Letter

June 12, 2017 11:33 AM EDT

Baird lowered its price target on Coherus Biosciences (NASDAQ: CHRS) to $37.00 (from $40.00) while maintaining a Outperform rating. Coherus announced the FDA issued a complete response letter for CHS-1701. The FDA is requesting a subset reanalysis with a revised immunogenicity assay as well as additional... More